Bayer Commits $1.55 Billion To Get Loxo’s Rare Cancer Drug

Bayer will pay $400 million — and up to $1.15 million more in milestones tied to regulatory approvals and sales — for commercial rights to a rare cancer drug being developed by Loxo Oncology, a small Stamford, Conn.-based biotechnology firm.November 14, 2017 at 08:03AM

via Forbes Real Time